THU0355 INFLUENCE OF ADALIMUMAB AND SULFASALAZINE ON STRUCTURE OF HYALINE CARTILAGE OF HIP JOINTS IN PATIENTS WITH ANKYLOSING SPONDILITIS
A. Petrov, H. Zayaeva, A. Petrov. Medical Academy named after Georgievsky, Crimean Federal university named after V.I. Vernadsky, Simferopol, Russian Federation Background: The impairment of hip joints has significant prognostic value on functional status of patients with Ankylosing spondylitis (AS) [1] . One of possible yearly marker of hip joints structure damage in patients with AS may be changing in volume of hyaline cartilage [2] . But clinical significance of this marker in monitoring of hip joint structure changes during treatment is underinvestigated. Objectives: To investigate changes in width of hyaline cartilage of hip joints in patients with AS under treatment with sulfasalazine and adalimumab during 12 month. Methods: The 53 patients with AS (42 male, 9 female, average age is 37.6 years old, duration of disease is 14-152 month) were included into study. All patients were treated by NSAIDs and sulfasalazine (2 g per day) at least 3 month before study. In treatment of 27 patients (1st group) was added adalimumab (40 mg subcutaneously every 2 weeks), other 26 patients (2nd group) were left on previous treatment regime. Patients were observed during 12 months of treatment including measurements of pain visual analog scale (VAS) in hip movements, maximal distance between ankles, pelvic X-ray and sonography of hip joints by 10-18 MHz probe. BASRI-Hips index was applied for radiographic estimation of structural damage of hip joints [3] . During sonography width of hip joint capsule and hyaline cartilage were measured. The Mann-Whitney-U test was used for comparison of changes in clinical and sonographic data between two groups of patients. Results: After 12 month treatment period in patients of 1st group in comparison with patients of 2nd group more significant decrease of pain VAS during hip movements (on 27.3 [18.8; 32.5] Background: Five different sub-cutaneous TNF alpha blockers (TNFb) are available for the treatment of NSAID-refractory and active axial spondyloarthritis (axSpA). The efficacy of these drugs in axSpA has been well reported in several RCT and real-life studies separately or as a group, but only very few head-to-head studies have compared each molecule's treatment effect in axSpA. Also, some data suggest that TNFb treatment effect in patients failing to a first TNFb is poorer than in TNFb-naïve patients, but some other suggest that response to a second TNFb might be comparable. Objectives: to describe TNFb prescription and treatment response of each TNFb, and to compare treatment response in TNFb-naïve/not naïve axSpA patients in a real-life setting. Methods: Prospective, multicenter, usual care study with 2 visits (baseline and 12 weeks after TNFb initiation, Predict-SpA study, ClinicalTrials.gov: NCT03039088)). Patients: axSpA patients (diagnosis according to treating rheumatologist) initiating a TNFb. Data collection: Patients and disease characteristics at baseline. Previous exposure to TNFb was collected. Disease activity and function measures were collected at both visits. The choice of the TNFb to be started during the trial was at the treating rheumatologist's discretion. Statistical analysis: effectiveness was defined by the BASDAI50 response. Non-responder imputation and baseline observation carried forward imputation (for binary and continuous outcome variables, respectively) were performed for patients who discontinued the TNFb treatment between baseline and the follow-up visit. Results: Among the 527 patients enrolled in the study, 508 patients were included in the analysis (1 patients was excluded due to missing data on all disease activity measures at baseline, and 18 patients were excluded due loss of follow-up between baseline and the follow-up visit). Mean age was 41.4 (±11.6), 237 (47%) were women, with a 6.1±8.5 mean disease duration. 377/508 (74%) were TNFb-naïve while 66 (13%), 35 (7%),19 (3.7%),8 (2%) and 3 (1%) had previously received, 1,2, 3, 4 and >4 TNFb, respectively. In the whole study population the most frequently prescribed TNFb was etanercept (197 (39%)), followed by adalimumab (131 (26%)), golimumab (88 (17%)), infliximab 53 (10%) and certolizumab (39 (8%)); the same order was observed in TNFb naïve patients; however, in patients previously exposed to TNFb, the most frequently prescribed TNFb was infliximab (31 (24%)) followed by golimumab (29 (22%)), adalimumab (29 (22%)), certolizumab (22 (17%)) and etanercept (20 (15%)). BASDAI50 responses were comparable for all TNFb molecules: 52%, 52%, 48%, 53% and 49% for etanercept, adalimumab, golimumab, infliximab and certolizumab, respectively. BASDAI 50 response was comparable in patients TNFb-naïve and patients previously exposed to only 1 previous TNFb (53% vs. 52%, for naïve vs. nonnaïve patients) but significantly decreased after (i.e. 37% and 36.% for patients previously exposed to 2 and to 3 or more TNFb) Conclusions: this study suggests that the TNFb treatment response is similar across the different available molecules but this treatment response decreased in case of a previous use of two TNFb. Interaction test between the presence of FM and the fulfillment of the EMA recommendation (defined by the presence of either structural radiographic damage of the SIJ or objective signs of inflammation (either elevated CRP or inflammation at MRI-SIJ)) on the anti TNF treatment response (BASDAI50) Results: Of the 508 enrolled pts (females: 46.7%, age: 41.4+11.6 years old, HLA B27 positive: 57.5%, X-Ray sacroiliitis: 53.2%, inflammation at MRI-SIJ: 52.0%), only 59 had no structural damage at SIJ-X-Rays and no inflammation at MRI-SIJ (12%). A concomitant FM was noticed in 42% vs 37% of pts treated in accordance vs not with the EMA recommendation, respectively (p=0.44). The anti-TNF treatment effect was higher in the groups of pts treated in accordance (vs not) with the EMA recommendation (BASDAI 50: 52% vs 39%, respectively; p=0.054). There was a trend (but not statistically significant) suggesting an interaction of the concomitant FM on the anti TNF treatment response with regard
